Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Priyadarshini

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Clinical and Experimental Dermatology|June 10, 2020
Interleukin-9 serves as a key link between systemic inflammation and angiogenesis in psoriasisH S Midde, M Priyadarssini, M Rajappa, et al.
International Urology and Nephrology|May 16, 2020
Asymmetric dimethylarginine and angiopoietin-like protein-2 are independent predictors of cardiovascular risk in pre-dialysis non-diabetic chronic kidney disease patientsK Ashokachakkaravarthy, Medha Rajappa, Sreejith Parameswaran, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trialT Powles, S A Hussain, M A Climent, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Clinical and Experimental Dermatology|June 10, 2020
Interleukin-9 serves as a key link between systemic inflammation and angiogenesis in psoriasisH S Midde, M Priyadarssini, M Rajappa, et al.
International Urology and Nephrology|May 16, 2020
Asymmetric dimethylarginine and angiopoietin-like protein-2 are independent predictors of cardiovascular risk in pre-dialysis non-diabetic chronic kidney disease patientsK Ashokachakkaravarthy, Medha Rajappa, Sreejith Parameswaran, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trialT Powles, S A Hussain, M A Climent, et al.
Pageof 2